Table 5.

Logistic regression analysis of subjects with subclinical hypothyroidism (kit manufacturer suggested TSH reference range is used).

	Crude model		Adjusted model
	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	P value
Male
Age (years)
19–29	Reference		Reference
30–39	0.63 (0.32–1.25)	0.290	0.58 (0.29–1.19)	0.136
40–49	0.70 (0.38–1.31)	0.507	0.66 (0.33–1.32)	0.236
50–59	0.75 (0.40–1.43)	0.706	0.62 (0.30–1.28)	0.196
60–69	0.75 (0.38–1.50)	0.720	0.60 (0.27–1.31)	0.199
70 and above	1.25 (0.43–3.62)	0.338	0.97 (0.32–2.93)	0.955
BMI (kg/m2)
<18.5	Reference
≥18.5, <23	1.48 (0.20–11.23)	0.793
≥23, <25	1.76 (0.12–13.68)	0.770
≥25	2.55 (0.34–19.08)	0.112
Region of residencea
Rural	Reference
Urban	0.72 (0.45–1.14)	0.163
Family history of thyroid disease
No	Reference
Yes	0.99 (0.30–3.22)	0.982
Smoking
No	Reference
Yes	0.57 (0.36–0.92)	0.022	0.58 (0.34–1.00)	0.048
UICRb
Quartile 1	Reference		Reference
Quartile 2	2.17 (1.06–4.43)	0.926	2.52 (1.27–5.02)	0.009
Quartile 3	2.93 (1.51–5.68)	0.110	3.57 (1.86–6.84)	0.001
Quartile 4	3.75 (1.92–7.34)	0.002	4.41 (2.28–8.52)	<0.001
Anti-TPO Ab
Absence	Reference		Reference
Presence	5.03 (2.68–9.45)	<0.001	5.59 (2.82–11.09)	<0.001
CKD stage
Stage 1, 2	Reference
Stage 3, 4, 5	0.70 (0.26–1.94)	0.495
Female
Age (years)
19–29	Reference		Reference
30–39	0.91 (0.49–1.69)	0.105	0.74 (0.40–1.36)	0.328
40–49	1.15 (0.64–2.07)	0.518	0.87 (0.48–1.58)	0.646
50–59	2.05 (1.19–3.53)	0.013	1.33 (0.76–2.35)	0.320
60–69	1.12 (0.62–2.04)	0.441	0.74 (0.39–1.42)	0.367
70–	2.14 (0.81–5.64)	0.194	1.61 (0.60–4.27)	0.341
BMI (kg/m2)
<18.5	Reference
≥18.5, <23	1.09 (0.53–2.26)	0.491
≥23, <25	1.54 (0.72–3.29)	0.144
≥25	1.27 (0.60–2.70)	0.757
Region of residencea
Rural	Reference
Urban	1.78 (1.15–2.75)	0.010
Family history of thyroid disease
No	Reference
Yes	0.81 (0.38–1.75)	0.597
Smoking
No	Reference
Yes	0.58 (0.30–1.11)	0.098	0.64 (0.33–1.23)	0.177
UICRb
Quartile 1	Reference		Reference
Quartile 2	1.18 (0.63–2.23)	0.350	1.17 (0.62–2.21)	0.636
Quartile 3	1.45 (0.83–2.54)	0.873	1.46 (0.82–2.60)	0.203
Quartile 4	2.34 (1.40–3.90)	<0.001	2.41 (1.44–4.05)	<0.001
Anti-TPO Ab
Absence	Reference		Reference
Presence	4.00 (2.59–6.16)	<0.001	4.06 (2.63–6.28)	<0.001
CKD stage
Stage 1, 2	Reference
Stage 3, 4, 5	0.85 (0.37–1.94)	0.695

*Data are presented OR (95% CI), statistics were carried out using logistic regression; ^aclassification of the area of residence is classified according to the administrative division of Korea; ^biodine intake status was evaluated by urine iodine creatinine ratio, quartile 1: <Q1 (141.53203438), quartile 2: ≥Q1 and <Q2 (281.81447737), quartile 3: ≥Q2 and <Q3 (664.64655625), quartile 4: ≥Q3.